

PROGRAMME AT A GLANCE

DAY 1: FRIDAY, AUGUST 2, 2024

BALLROOM 1	BALLROOM 2
Registration & Breakfast 7:30 AM - 8:30 AM	
S01 - Opening Address 8:30 AM - 8:45 AM	
S02 - Haematology Track 8:45 AM - 10:00 AM	
Tea Break & Visit Exhibitions 10:00AM - 11:00 AM	
S03 - Improving Outcomes In Patients With HR+/HER2- Advanced Breast Cancer Amidst A Rapidly Evolving Treatment Landscape Supported by: Novartis 11:00 AM - 11:45 AM	
S04 - Breast Track 11:45 AM - 1:00 PM	
S05 - Advances in the Management of Locally Advanced, Recurrent/metastatic Cervical Cancer and R/M Endometrial Cancer Supported by: MSD Pharma 1:00 PM - 2:00 PM	
Lunch & Visit Exhibitions 2:00 PM - 3:00 PM	
S06 - Sarcoma Track 3:00 PM - 4:15 PM	S07 - Radiation Oncology Track 3:00 PM - 4:15 PM
	S08 - Updates in First-Line Systemic Treatment of Hepatocellular Carcinoma Supported by: Bristol-Myers Squibb 4:15 PM - 4:45 PM
S09 - Survivorship/ Supportive Care Track 4:45 PM - 6:00 PM	S10 - Head & Neck Track 4:45 PM - 6:00 PM

DAY 3: SUNDAY, AUGUST 4, 2024

BALLROOM 1 & 2

Registration & Breakfast 8:00 AM - 9:00 AM
S23 - SSO - CIC 9:00 AM - 12:30 PM

DAY 2: SATURDAY, AUGUST 3, 2024

BALLROOM 1	BALLROOM 2
Registration & Breakfast 8:00 AM - 8:45 AM	
S11 - Changing Treatment Paradigm in Recurrent/Metastatic Nasopharyngeal Cancer Supported by: BeiGene 8:45 AM - 9:15 AM	S12 - The Evolving Landscape of Urothelial Cancer Management (La/mUC) – Enfortumab Vedotin + Pembrolizumab as First Line Therapy Supported by: Astellas Pharma 8:45 AM - 9:15 AM
S13 - COVID-19 and Oncology: Navigating the Impact on Cancer Care Supported by: Pfizer 9:15 AM - 10:00 AM	
S14 - Gynaecology Track 10:00 AM - 11:15 AM	S15 - Genitourinary Track 10:00 AM - 11:15 AM
	S16 - Precision Strikes With PSMA-targeted Theranostics Supported by: Novartis 11:15 AM - 12:15 PM
Lunch & Visit Exhibitions 12:15 PM - 1:00 PM	
S17 - Current Treatment Options for the Management of HER2m NSCLC- T-Dxd Experience and Case Discussions Supported by: Daiichi Sankyo 1:00 PM - 2:00 PM	
S18 - Lung Track 2:00 PM - 3:15 PM	
S19 - Subcutaneous Immunotherapy: Pioneering the Next Standard in Treatment Supported by: Roche 3:15 PM - 4:00 PM	
S20 - Transforming Management of mCRC with BRAF Mutation in Real World Setting Supported by: Pierre Fabre 4:00 PM - 4:30 PM	
S21 - Gastrointestinal Track 4:30 PM - 5:45 PM	
S22 - Closing Address 5:45 PM - 6:00 PM	

